Abstract
The aim of this study was to assess the effect of newly synthesized derivatives of 4-aminopyridine (4-AP) on cuprizone-induced model of brain demyelination in mice. 4-AP is already approved for the treatment of walking difficulties in patients with multiple sclerosis. The model of demyelination was carried out by the administration of cuprizone to the drinking water of the experimental mice. Besides cuprizone, 4-AP derivatives and 4-AP were administered to the groups in order to assess their protective effect on the demyelination. We used immunohistochemistry for visualization of changes in corpus callosum. Memory storage processes were also assessed with the passive avoidance test on the last two days of the experiment. The experimental mice treated with compounds 4b and 4c increased significantly their latency time on the second day in comparison to the control group which indicated an improved memory process. The number of mature oligodendrocytes in the groups treated with compounds 4b, 4c and 4-AP is closer to those in the control group. The results of our studies showed that the newly synthesized compounds 4b and 4c reverse the effect of cuprizone. These groups also showed increased latency time in the passive avoidance test in comparison to the control group.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Acs P, Selak MA, Komoly S, Kalman B (2013) Distribution of oligodendrocyte loss and mitochondrial toxicity in the cuprizone-induced experimental demyelination model. J Neuroimmunol 262:128–131. https://doi.org/10.1016/j.jneuroim.2013.06.012
Asano M, Wakabayashi T, Ishikawa K, Kishimoto H (1978) Mechanism of the formation of megamitochondria by copper-chelating agents. IV. Role of fusion phenomenon in the cuprizone-induced megamitochondrial formation. Acta Pathol Jpn 28:205–213. https://doi.org/10.1111/j.1440-1827.1978.tb00532.x
Bacia A, Wollmann R, Soliven B (2004) K+ channel blockade impairs remyelination in the cuprizone model. Glia 48:156–165. https://doi.org/10.1002/glia.20067
Bakker DA, Ludwin SK (1987) Blood-brain barrier permeability during cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases. J Neurol Sci 78:125–137. https://doi.org/10.1016/0022-510X(87)90055-4
Biancotti JC, Kumar S, de Vellis J (2008) Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair. Neurochem Res 33:2615–2628. https://doi.org/10.1007/s11064-008-9792-8
Blakemore W (1972) Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. J Neurocytol 1:413–426. https://doi.org/10.1007/BF01102943
Carlton WW (1969) Spongiform encephalopathy induced in rats and guinea pigs by cuprizone. Exp Mol Pathol 10:274–287. https://doi.org/10.1016/0014-4800(69)90057-4
Dietrich M, Koska V, Hecker C et al (2020) Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. Brain 143(4):1127–1142. https://doi.org/10.1093/brain/awaa062
Fischbach F, Nedelcu J, Leopold P, Zhan J, Clarner T, Nellessen L, Beißel C, van Heuvel Y, Goswami A, Weis J, Denecke B, Schmitz C, Hochstrasser T, Nyamoya S, Victor M, Beyer C, Kipp M (2019) Cuprizone-induced graded oligodendrocyte vulnerability is regulated by the transcription factor DNA damage-inducible transcript 3. Glia 67:263–276. https://doi.org/10.1002/glia.23538
Franco-Pons N, Torrente M, Colomina MT, Vilella E (2007) Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett 169:205–213. https://doi.org/10.1016/j.toxlet.2007.01.010
Gallo V, Zhou JM, McBain CJ, Wright P, Knutson PL, Armstrong RC (1996) Oligodendrocyte progenitor cell proliferation and lineage progression are regulated by glutamate receptor-mediated K-channel block. J Neurosci 16:2659–2670. https://doi.org/10.1523/JNEUROSCI.16-08-02659.1996
Gudi V, Gingele S, Skripuletz T, Stangel M (2014) Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front Cell Neurosci 8:73. https://doi.org/10.3389/fncel.2014.00073
Hiremath MM, Saito Y, Knapp GW, Ting JP-Y, Suzuki K, Matsushima GK (1998) Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 92:38–49. https://doi.org/10.1016/S0165-5728(98)00168-4
Judge SI, Bever CT Jr (2006) Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 111:224–259. https://doi.org/10.1016/j.pharmthera.2005.10.006
Kashani IR, Chavoshi H, Pasbakhsh P, Hassani M, Omidi A, Mahmoudi R, Beyer C, Zendedel A (2017) Protective effects of erythropoietin against cuprizone-induced oxidative stress and demyelination in the mouse corpus callosum. Iran J Basic Med Sci 20:886–893. https://doi.org/10.22038/ijbms.2017.9110
Kondo A, Nakano T, Suzuki K (1987) Blood-brain barrier permeability to horseradish peroxidase in twitcher and cuprizone-intoxicated mice. Brain Res 425:186–190. https://doi.org/10.1016/0006-8993(87)90499-9
Kostadinova I, Danchev N (2019) 4-aminopyridine—the new old drug for the treatment of neurodegenerative diseases. Pharmacia 66:67–74. https://doi.org/10.3897/pharmacia.66.e35976
Kostadinova I, Landzhov B, Danchev N, Vezenkov L, Oskar A (2020) Effect of 4- aminopyridine and newly synthesized 4-aminopyridine derivatives on cuprizone-induced demyelination of corpus callosum in mice. C R Acad Bulg Sci 73:1137–1142. https://doi.org/10.7546/CRABS.2020.08.13
Love S (1988) Cuprizone neurotoxicity in the rat: morphologic observations. J Neurol Sci 84:223–237. https://doi.org/10.1016/0022-510X(88)90127-X
Mason JL, Ye P, Suzuki K, D’Ercole AJ, Matsushima GK (2000) Insulin like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci 20:5703–5708. https://doi.org/10.1523/JNEUROSCI.20-15-05703.2000
Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107–116. https://doi.org/10.1111/j.1750-3639.2001.tb00385.x
Morell P, Barrett CV, Mason JL, Toews AD, Hostettler JD, Knapp GW, Matsushima GK (1998) Gene expression in the brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci 12:220–227. https://doi.org/10.1006/mcne.1998.0715
Moriguchi K, Miyamoto K, Fukumoto Y, Kusunoki S (2018) 4-Aminopyridine ameliorates relapsing remitting experimental autoimmune encephalomyelitis in SJL/J mice. J Neuroimmunol 323:131–135. https://doi.org/10.1016/j.jneuroim.2018.08.007
Pandit L, Murthy JM (2011) Treatment of multiple sclerosis. Ann Indian Acad Neurol 14:65–69. https://doi.org/10.4103/0972-2327.83094
Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego
Praet J, Guglielmetti C, Berneman Z, Van der Linden A, Ponsaerts P (2014) Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci Biobehav Rev 47:485–505. https://doi.org/10.1016/j.neubiorev.2014.10.004
Shrager P, Novakovic SD (1995) Control of myelination, axonal growth, and synapse formation in spinal cord explants by ion channels and electrical activity. Dev Brain Res 88:68–78. https://doi.org/10.1016/0165-3806(95)00081-N
Strijbis EM, Bijvank JAN, Killestein J (2020) 4-Aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect—yes. Mult Scler 26(11):1309–1310. https://doi.org/10.1177/1352458520923951
Tandler B, Hoppel CL (1975) The failure of supplemental dietary copper to prevent cuprizone-induced alterations in mouse hepatocytes. Beitr Pathol 156:56–64. https://doi.org/10.1016/S0005-8165(75)80085-0
Venturini G (1973) Enzymic activities and sodium, potassium and copper concentrations in mouse brain and liver after cuprizone treatment in vivo. J Neurochem 21:1147–1151. https://doi.org/10.1111/j.1471-4159.1973.tb07569.x
Vezenkov L, Zaharieva D, Danchev N, Vassilev N, Bakalova A, Ivanov T (2014) Synthesis of 4-aminopyridine derivatives comprising peptide moiety designed for prevention and treatment of Alzheimer’s disease and multiple sclerosis. In: Proceedings of the 33rd European peptide symposium, pp 200–201
Wagner T, Rafael J (1977) Biochemical properties of liver megamitochondria induced by chloramphenicol or cuprizone. Exp Cell Res 107:1–13. https://doi.org/10.1016/0014-4827(77)90379-2
Wakabayashi T, Asano M, Ishikawa K, Kishimoto H (1978) Mechanism of the formation of megamitochondria by copper-chelating agents. V. Further studies on isolated megamitochondria. Acta Pathol Jpn 28:215–223. https://doi.org/10.1111/j.1440-1827.1978.tb00533.x
Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, Langer-Gould A (2019) Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol 6:1905–1922. https://doi.org/10.1002/acn3.50862
Xu C, Bailly-Maitre B, Reed JC (2005) Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115:2656–2664. https://doi.org/10.1172/JCI26373
Funding
This work was supported by the Medical University of Sofia, Bulgaria [Project №82/23.04.2019] from the competition “Grant 2019”.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. The synthesis of 4-aminopyridine derivatives was performed by LV. Material preparation, data collection and analysis were performed by IK, BL, LM, and ND. The first draft of the manuscript was written by IK and BL and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to declare that are relevant to the content of this article.
Research involving human participants and/or animals
This article does not contain any studies with human participants. All animal experiments comply with the ARRIVE guidelines and were carried out in accordance with the EU Directive 2010/63/EU for animal experiments.
Consent for publication
All authors agree with the content and all gave explicit consent for the submission of this article.
Additional information
Handling editor: M. Engelmann.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kostadinova, I., Landzhov, B., Marinov, L. et al. Neuroprotective effect of newly synthesized 4-aminopyridine derivatives on cuprizone-induced demyelination in mice—a behavioral and immunohistochemical study. Amino Acids 53, 1279–1286 (2021). https://doi.org/10.1007/s00726-021-03035-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-021-03035-2